Carfilzomib (PR-171)
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| F1300-5MG | 5 mg | 106,00 | Add | |
| F1301-25MG | 25 mg | 317,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Please inquire a quote for two or more UBPBio products
Carfilzomib is a derivative of the microbially-derived natural product epoxomycin. It irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome with high potency and selectivity at several orders of magnitude over epoxomycin. In 2012, Carfilzomib was approved by the FDA for use in patients with relapsed and refractory multiple myeloma. It is in clinical trials for other cancers as well
| Category | Inhibitor |
| Supplier | UBPBio |
| Regulatory Status | RUO |
| Format | Powder; no buffer |
| CAS-Number | 868540-17-4 |
| Storage Conditions | -20°C |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.ubpbio.com |
| Shipping Details | Ambient temp. |
| Material Safety Data Sheet | Download PDF |
